Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Assess Adverse Events, Tolerability, and Pharmacokinetics of Subcutaneous Injections of ABBV-295 in Healthy Adult Japanese Participants With Overweight or Obesity.
Sponsor: AbbVie
Summary
The purpose of this study is to assess the adverse events, tolerability, and Pharmacokinetics (PK) of subcutaneous injections of ABBV-295 in healthy adult Japanese participants with overweight or obesity.
Official title: A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABBV-295 in Healthy Japanese Subjects With Overweight or Obesity
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
24
Start Date
2026-03-31
Completion Date
2027-01
Last Updated
2026-04-07
Healthy Volunteers
Yes
Conditions
Interventions
ABBV-295
Subcutaneous Injections
Placebo for ABBV-295
Subcutaneous Injections
Locations (1)
CenExel ACT- Anaheim Clinical Trials /ID# 280879
Anaheim, California, United States